Sionna Therapeutics (NASDAQ:SION) Stock Rating Upgraded by Royal Bank Of Canada

Sionna Therapeutics (NASDAQ:SION) was upgraded by stock analysts at Royal Bank Of Canada from an “underperform” rating to a “sector perform” rating in a research note issued to investors on Monday. The brokerage presently has a $5.00 price objective on the stock. Royal Bank Of Canada’s target price points to a potential upside of 23.30% from the stock’s previous close.

Several other analysts have also recently commented on the stock. JonesTrading lifted their target price on shares of Sionna Therapeutics from $52.00 to $63.00 and gave the stock a “buy” rating in a research note on Tuesday, April 28th. Stifel Nicolaus restated a “hold” rating and set a $7.00 price objective on shares of Sionna Therapeutics in a report on Monday. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $59.00 price objective on shares of Sionna Therapeutics in a research report on Thursday. Guggenheim increased their target price on Sionna Therapeutics from $50.00 to $60.00 and gave the stock a “buy” rating in a research report on Friday. Finally, Citizens Jmp reissued a “market outperform” rating and issued a $63.00 price target on shares of Sionna Therapeutics in a research note on Tuesday, May 26th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Sionna Therapeutics has a consensus rating of “Hold” and a consensus target price of $42.22.

Sionna Therapeutics Stock Performance

Sionna Therapeutics stock traded down $46.98 during midday trading on Monday, reaching $4.05. 23,315,454 shares of the company were exchanged, compared to its average volume of 548,288. The firm’s 50-day simple moving average is $42.35 and its 200-day simple moving average is $40.42. Sionna Therapeutics has a 1 year low of $4.01 and a 1 year high of $54.97. The company has a market capitalization of $183.33 million, a price-to-earnings ratio of -1.88 and a beta of 1.32.

Sionna Therapeutics (NASDAQ:SION) last released its earnings results on Thursday, August 6th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.02). On average, analysts forecast that Sionna Therapeutics will post -2.63 EPS for the current fiscal year.

Insider Activity

In other news, Director Orbimed Advisors Llc sold 85,918 shares of the business’s stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $44.86, for a total transaction of $3,854,281.48. Following the completion of the sale, the director owned 2,469,959 shares in the company, valued at approximately $110,802,360.74. The trade was a 3.36% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Peter A. Thompson sold 85,918 shares of the stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $44.86, for a total transaction of $3,854,281.48. Following the sale, the director directly owned 2,469,959 shares of the company’s stock, valued at approximately $110,802,360.74. This trade represents a 3.36% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 403,726 shares of company stock valued at $18,259,354 over the last 90 days. 5.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Sionna Therapeutics

Institutional investors have recently bought and sold shares of the business. Goldman Sachs Group Inc. acquired a new stake in shares of Sionna Therapeutics in the first quarter worth $667,000. Woodline Partners LP acquired a new stake in Sionna Therapeutics in the 1st quarter valued at $837,000. Geode Capital Management LLC raised its position in Sionna Therapeutics by 113.4% in the second quarter. Geode Capital Management LLC now owns 289,275 shares of the company’s stock valued at $5,020,000 after purchasing an additional 153,712 shares during the period. Rhumbline Advisers acquired a new stake in shares of Sionna Therapeutics in the second quarter valued at about $307,000. Finally, New York State Common Retirement Fund acquired a new position in Sionna Therapeutics during the 2nd quarter worth approximately $118,000.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.